Bausch + Lomb Corporation (BLCO) News
Filter BLCO News Items
BLCO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest BLCO News From Around the Web
Below are the latest news stories about BAUSCH & LOMB CORP that investors may wish to consider to help them evaluate BLCO as an investment opportunity.
Bausch + Lomb CEO Brent Saunders Pays $35.35 Million for Cher’s Former Miami Beach HomeBausch + Lomb CEO Brent Saunders has purchased Cher’s former waterfront home in Miami Beach, Fla., for $35.35 million. The La Gorce Island home, which Cher owned in the 1990s, hit the market three months ago for $42.5 million. Saunders, who is also the former CEO of the Botox maker Allergan, said he bought the property with his wife, Daniela Botero Correa. |
Is Bausch + Lomb Corporation (NYSE:BLCO) Trading At A 39% Discount?Key Insights Using the 2 Stage Free Cash Flow to Equity, Bausch + Lomb fair value estimate is US$25.50 Current share... |
Bausch + Lomb Reports More Than 76 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling ProgramsVAUGHAN, Ontario, November 15, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ONE by ONE and Biotrue Eye Care Recycling programs have collected a total of 76,645,000 million units, or 464,100 pounds, of used contact lenses, eye care and lens care materials in the United States, which is equivalent to the weight of 140 hippos1. |
Bausch & Lomb Corp (BLCO) Reports Q3 2023 Earnings and Raises Full-Year GuidanceRevenue Grows 7% to $1.007 Billion, Despite Net Loss of $84 Million |
Bausch + Lomb Announces Third-Quarter 2023 Results and Raises Full-Year 2023 GuidanceVAUGHAN, Ontario, November 01, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2023 financial results. |
Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Ophthalmology Annual MeetingVAUGHAN, Ontario, October 26, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced three podium presentations and seven poster presentations during the American Academy of Ophthalmology (AAO) annual meeting, which will take place in San Francisco Nov. 3-6, 2023. |
Bausch + Lomb Will Release Third-Quarter 2023 Financial Results on November 1VAUGHAN, Ontario, October 16, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter 2023 financial results on Wednesday, Nov. 1, 2023. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of |
Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Optometry Annual MeetingVAUGHAN, Ontario, October 04, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced one podium presentation and four poster presentations during the American Academy of Optometry (AAOpt) annual meeting, which will take place in New Orleans Oct. 11-14, 2023. |
Bausch Health's Bausch + Lomb Announces Completion of the Acquisition of XIIDRA(R)LAVAL, QC / ACCESSWIRE / September 29, 2023 / Bausch + Lomb Corporation ("Bausch + Lomb") (NYSE/TSX:BLCO), a subsidiary of Bausch Health Companies Inc. (the "Company" or "Bausch Health") (NYSE/TSX:BHC), today announced it has completed its acquisition ... |
Bausch + Lomb Completes Acquisition of XIIDRA®VAUGHAN, Ontario, September 29, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced it has completed its acquisition of XIIDRA (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease (DED) focusing on inflammation associated with dry eye, and certain other ophthalmology assets. |